JP2011528713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528713A5 JP2011528713A5 JP2011520110A JP2011520110A JP2011528713A5 JP 2011528713 A5 JP2011528713 A5 JP 2011528713A5 JP 2011520110 A JP2011520110 A JP 2011520110A JP 2011520110 A JP2011520110 A JP 2011520110A JP 2011528713 A5 JP2011528713 A5 JP 2011528713A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 201000009910 diseases by infectious agent Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 102000033147 ERVK-25 Human genes 0.000 claims 1
- 108091005771 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (8)
- 式（Ｉ）：
- 請求項１に記載の化合物の有効量と、薬学的に許容される担体とを含んでなる医薬組成物。
- ＨＣＶプロテアーゼ阻害剤及びＨＣＶ ＮＳ５Ｂポリメラーゼ阻害剤からなる群より選択される、第２の治療剤をさらに含んでなる、請求項２に記載の医薬組成物。
- 医薬における使用のための、請求項１に記載の化合物。
- ＨＣＶ感染症の予防又は治療における使用のための、請求項１に記載の化合物。
- ＨＣＶ ＮＳ３プロテアーゼ活性を、そのことを必要とする患者において阻害するための、医薬の調製における、請求項１ないし３のいずれか１項に記載の化合物又は組成物の使用。
- ＨＣＶによる感染症を、そのことを必要とする患者において予防又は治療するための、医薬の調製における、請求項１ないし３のいずれか１項に記載の化合物又は組成物の使用。
- ＨＣＶ感染症を予防又は治療するための医薬組成物であって、請求項１ないし３のいずれか１項に記載の化合物の有効量と、薬学的に許容される担体を含んでなる、該医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13555908P | 2008-07-22 | 2008-07-22 | |
| US61/135,559 | 2008-07-22 | ||
| PCT/US2009/050915 WO2010011566A1 (en) | 2008-07-22 | 2009-07-17 | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528713A JP2011528713A (ja) | 2011-11-24 |
| JP2011528713A5 true JP2011528713A5 (ja) | 2012-01-26 |
| JP4920797B2 JP4920797B2 (ja) | 2012-04-18 |
Family
ID=41130248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011520110A Active JP4920797B2 (ja) | 2008-07-22 | 2009-07-17 | Ｈｃｖｎｓ３プロテアーゼ阻害剤としてのマクロ環式キノキサリン化合物 |
Country Status (44)
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| MY164469A (en) | 2006-10-27 | 2017-12-15 | Msd Italia Srl | Hcv ns3 protease inhibitors |
| CA2720850A1 (en) * | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| CA2731177C (en) | 2008-07-22 | 2013-10-29 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
| US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
| AU2010229833B2 (en) | 2009-03-27 | 2014-03-13 | Merck Sharp & Dohme Llc | Inhibitors of hepatitis C virus replication |
| JP5639155B2 (ja) * | 2009-05-13 | 2014-12-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルスインヒビターとしての大環状化合物 |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| NZ591973A (en) * | 2009-06-11 | 2013-03-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| SG188618A1 (en) * | 2010-09-21 | 2013-04-30 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| US9254292B2 (en) | 2010-09-29 | 2016-02-09 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| US20130280214A1 (en) * | 2010-09-29 | 2013-10-24 | Merck Sharp & Dohme Corp. | Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases |
| EP2651884A2 (en) | 2010-12-14 | 2013-10-23 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US9249204B2 (en) * | 2011-06-01 | 2016-02-02 | Jyant Technologies, Inc. | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| KR20140059236A (ko) * | 2011-08-19 | 2014-05-15 | 머크 샤프 앤드 돔 코포레이션 | Hcv 프로테아제 억제제의 결정 형태 |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| ES2529143B1 (es) | 2011-10-21 | 2015-10-26 | Abbvie Inc. | Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc |
| GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
| EP2773342A4 (en) * | 2011-10-31 | 2015-08-26 | Merck Sharp & Dohme | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES |
| WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| UA119315C2 (uk) * | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| DK2909205T3 (en) | 2012-10-19 | 2017-03-06 | Bristol Myers Squibb Co | 9-METHYL-SUBSTITUTED HEXADECAHYDROCYCLOPROPA (E) PYRROL (1,2-A) (1,4) DIAZOCYCLOPENTADECINYLCARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR TREATMENT |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014110687A1 (en) | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US9617310B2 (en) * | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
| SG11201602693QA (en) | 2013-10-18 | 2016-05-30 | Merck Sharp & Dohme | Methods and intermediates for preparing macrolactams |
| WO2015095430A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Methods and intermediates for the preparation of macrolactams |
| JP6568541B2 (ja) * | 2013-12-23 | 2019-08-28 | ギリアド ファーマセット エルエルシー | 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態 |
| US9440991B2 (en) * | 2013-12-23 | 2016-09-13 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| EP3102210A4 (en) * | 2014-02-05 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmaceutical composition of selective hcv ns3/4a inhibitors |
| CA2937942A1 (en) * | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| EP3151850A4 (en) | 2014-06-06 | 2017-11-29 | AbbVie Inc. | Crystal forms |
| US20180228826A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| WO2017023716A1 (en) * | 2015-08-04 | 2017-02-09 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
| CN105753806B (zh) * | 2016-02-02 | 2018-06-05 | 厦门市蔚嘉化学科技有限公司 | 一种利托那韦中间体的非均相合成方法及其应用 |
| EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017198102A1 (zh) * | 2016-05-16 | 2017-11-23 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的大环喹喔啉化合物及其药物组合物及应用 |
| RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
| WO2020247736A1 (en) * | 2019-06-07 | 2020-12-10 | University Of Massachusetts | Hepatitis c virus ns3/4a protease inhibitors |
| CN111057045A (zh) * | 2019-12-18 | 2020-04-24 | 安徽红杉生物医药科技有限公司 | Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用 |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3480613A (en) * | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
| US6128582A (en) | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
| AU757783B2 (en) | 1997-08-11 | 2003-03-06 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
| HUP0100100A3 (en) | 1997-08-11 | 2001-12-28 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use |
| IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
| CN100349913C (zh) | 1998-02-25 | 2007-11-21 | 埃莫里大学 | 2′－氟代核苷 |
| GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
| ES2281170T3 (es) | 1998-03-31 | 2007-09-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c. |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| US6602982B1 (en) | 1998-08-10 | 2003-08-05 | Hokkaido Electric Power Company, Incorporated | Process for the preparation of regular glycopeptides |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| WO2000025780A1 (en) | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| JP4773010B2 (ja) | 1999-06-25 | 2011-09-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｉｍｐｄｈのカーバメート阻害剤のプロドラッグ |
| CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
| US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
| CN1427722A (zh) | 2000-02-18 | 2003-07-02 | 希拉生物化学股份有限公司 | 用核苷类似物治疗或预防黄病毒感染的方法 |
| US6727267B2 (en) | 2000-04-05 | 2004-04-27 | Tularik Inc. | NS5B HVC polymerase inhibitors |
| JP4748911B2 (ja) | 2000-04-05 | 2011-08-17 | シェーリング コーポレイション | Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤 |
| EP1284741B1 (en) | 2000-04-13 | 2008-11-19 | Pharmasset, Inc. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| WO2001092282A2 (en) | 2000-05-26 | 2001-12-06 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| US6921735B2 (en) | 2000-08-10 | 2005-07-26 | The Trustees Of Boston College | Recyclable metathesis catalysts |
| US6955174B2 (en) * | 2000-08-18 | 2005-10-18 | Uryovascular Systems, Inc. | Cryotherapy method for detecting and treating vulnerable plaque |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| WO2002020497A1 (fr) | 2000-09-01 | 2002-03-14 | Shionogi & Co., Ltd. | Composés ayant une action inhibitrice du virus de l'hépatite c |
| PT1411954E (pt) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
| CN1301994C (zh) | 2000-12-12 | 2007-02-28 | 先灵公司 | 作为c型肝炎病毒ns3－丝氨酸蛋白酶抑制剂的二芳基肽 |
| WO2002048116A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
| CA2429352A1 (en) | 2000-12-15 | 2002-06-20 | Lieven Stuyver | Antiviral agents for treatment of flaviviridae infections |
| JPWO2002051425A1 (ja) | 2000-12-26 | 2004-04-22 | 三菱ウェルファーマ株式会社 | Ｃ型肝炎治療剤 |
| EP2360166A1 (en) | 2001-01-22 | 2011-08-24 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| JP4537057B2 (ja) | 2001-08-14 | 2010-09-01 | テルアビブ・ユニバーシティ・フューチャー・テクノロジー・デベロップメント・エルピー | 脂質化グリコサミノグリカン粒子ならびに診断及び処置のための薬物及び遺伝子送達におけるその使用 |
| US7138376B2 (en) | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
| JP2005536440A (ja) | 2001-09-28 | 2005-12-02 | イデニクス（ケイマン）リミテツド | ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
| US7282512B2 (en) | 2002-01-17 | 2007-10-16 | Smithkline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors |
| GB0201179D0 (en) | 2002-01-18 | 2002-03-06 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| EP1476169B1 (en) | 2002-02-13 | 2013-03-20 | Merck Sharp & Dohme Corp. | Inhibiting orthopoxvirus replication with nucleoside compounds |
| US6777392B2 (en) | 2002-03-28 | 2004-08-17 | Council Of Scientific And Industrial Research | 8-(C-β-D-glucopyranosyl)-7, 3', 4'-trihydroxyflavone, process of isolation thereof, pharmaceutical composition and method for the treatment of diabetes |
| US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| JP2005530843A (ja) | 2002-06-21 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害剤としてのヌクレオシド誘導体 |
| JP2006512288A (ja) | 2002-06-27 | 2006-04-13 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体 |
| PL374831A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
| CA2489552A1 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| WO2004003000A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
| JP2005533108A (ja) | 2002-07-16 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体 |
| EP1527082A2 (en) | 2002-07-25 | 2005-05-04 | Micrologix Biotech, Inc. | Anti-viral 7-deaza d-nucleosides and uses thereof |
| AU2003257157C1 (en) | 2002-08-01 | 2010-03-18 | Pharmasset Inc. | Compounds with the bicyclo[4.2.1] nonane system for the treatment of Flaviviridae infections |
| CA2499253A1 (en) | 2002-09-30 | 2004-04-08 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
| US7265152B2 (en) | 2002-11-01 | 2007-09-04 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases |
| US20040254159A1 (en) * | 2003-02-27 | 2004-12-16 | Hasvold Lisa A. | Heterocyclic kinase inhibitors |
| CA2516016C (en) * | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| JP2006522017A (ja) | 2003-04-02 | 2006-09-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウイルスプロテアーゼインヒビターのための医薬組成物 |
| GB0307891D0 (en) | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| ATE422895T1 (de) * | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| UY28323A1 (es) * | 2003-05-21 | 2004-12-31 | Boehringer Ingelheim Int | Compuestos inhibidores de la hepatitis c |
| EP1633766B1 (en) | 2003-05-30 | 2019-03-06 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
| GB0313250D0 (en) | 2003-06-09 | 2003-07-16 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| KR20060026426A (ko) * | 2003-06-19 | 2006-03-23 | 에프. 호프만-라 로슈 아게 | 4'-아지도 뉴클레오사이드 유도체의 제조 방법 |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| GB0321003D0 (en) | 2003-09-09 | 2003-10-08 | Angeletti P Ist Richerche Bio | Compounds, compositions and uses |
| GB0323845D0 (en) | 2003-10-10 | 2003-11-12 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP1730167B1 (en) | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
| DE602005013922D1 (de) | 2004-02-24 | 2009-05-28 | Japan Tobacco Inc | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
| GB0413087D0 (en) | 2004-06-11 | 2004-07-14 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0416396D0 (en) | 2004-07-22 | 2004-08-25 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| ES2327252T3 (es) | 2004-08-23 | 2009-10-27 | F. Hoffmann-La Roche Ag | 4'-azido nucleosidos antivirales. |
| GB0419850D0 (en) | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| AU2005298403A1 (en) | 2004-10-26 | 2006-05-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| US7834145B2 (en) | 2005-03-22 | 2010-11-16 | Merck Sharp & Dohme Corp. | HCV protease substrates |
| CA2606195C (en) * | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
| GB0509326D0 (en) | 2005-05-09 | 2005-06-15 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| US7462035B2 (en) | 2005-07-27 | 2008-12-09 | Physical Optics Corporation | Electrical connector configured as a fastening element |
| CA2615896C (en) | 2005-08-01 | 2012-11-13 | Merck & Co., Inc. | Macrocyclic peptides as hcv ns3 protease inhibitors |
| WO2007028789A1 (en) | 2005-09-07 | 2007-03-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Quinazoline derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0519797D0 (en) | 2005-09-29 | 2005-11-09 | Istituto Di Ricerche D Biolog | Therapeutic agents |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| EP2029741A4 (en) | 2006-06-08 | 2011-03-16 | Merck Sharp & Dohme | QUICK PROCEDURE FOR DETERMINING THE HEMMERSENSITIVITY OF NS3 / 4A PROTEASE SEQUENCES CLONED FROM CLINICAL SAMPLES |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| TWI454264B (zh) * | 2006-06-26 | 2014-10-01 | Enanta Pharm Inc | 喹啉基巨環ｃ型肝炎病毒絲胺酸蛋白酶抑制劑 |
| US8138164B2 (en) * | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| AU2007309488B2 (en) * | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| WO2008051477A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| WO2008057208A2 (en) * | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| MY164469A (en) | 2006-10-27 | 2017-12-15 | Msd Italia Srl | Hcv ns3 protease inhibitors |
| JP2010509080A (ja) | 2006-11-09 | 2010-03-25 | ツインブレード、テクノロジーズ、ホールディング、スウェーデン、アクチボラグ | ハブ装置 |
| US20100143886A1 (en) | 2007-03-09 | 2010-06-10 | Ludmerer Steven W | In vivo hcv resistance to anti-viral inhibitors |
| AR067182A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Moduladores del receptor 7 tipo toll |
| JP5433573B2 (ja) | 2007-07-19 | 2014-03-05 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | 抗ウイルス剤としての大環状化合物 |
| MX2010005261A (es) | 2007-11-14 | 2010-10-15 | Enanta Pharm Inc | Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo. |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| CA2720850A1 (en) * | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| CA2731177C (en) | 2008-07-22 | 2013-10-29 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
-
2009
- 2009-07-17 CA CA2731177A patent/CA2731177C/en active Active
- 2009-07-17 ME MEP-2012-463A patent/ME02024B/me unknown
- 2009-07-17 DK DK09790553.3T patent/DK2310095T3/da active
- 2009-07-17 EA EA201170241A patent/EA019327B1/ru active Protection Beyond IP Right Term
- 2009-07-17 ME MEP-2014-375A patent/ME02132B/me unknown
- 2009-07-17 WO PCT/US2009/050915 patent/WO2010011566A1/en active Application Filing
- 2009-07-17 ES ES12181546.8T patent/ES2491090T3/es active Active
- 2009-07-17 PL PL09790553T patent/PL2310095T3/pl unknown
- 2009-07-17 PL PL12181546T patent/PL2540350T3/pl unknown
- 2009-07-17 CN CN200980137118.6A patent/CN102159285B/zh active Active
- 2009-07-17 EP EP09790553A patent/EP2310095B1/en active Active
- 2009-07-17 AU AU2009274190A patent/AU2009274190B2/en active Active
- 2009-07-17 DK DK12181546.8T patent/DK2540350T3/da active
- 2009-07-17 PE PE2011000067A patent/PE20110212A1/es active IP Right Grant
- 2009-07-17 PT PT09790553T patent/PT2310095E/pt unknown
- 2009-07-17 UA UAA201102068A patent/UA100436C2/uk unknown
- 2009-07-17 MY MYPI20110310 patent/MY152070A/en unknown
- 2009-07-17 JP JP2011520110A patent/JP4920797B2/ja active Active
- 2009-07-17 ES ES09790553T patent/ES2392611T3/es active Active
- 2009-07-17 SI SI200930359T patent/SI2310095T1/sl unknown
- 2009-07-17 NZ NZ590638A patent/NZ590638A/en unknown
- 2009-07-17 BR BRPI0916235A patent/BRPI0916235B8/pt active IP Right Grant
- 2009-07-17 EP EP12181546.8A patent/EP2540350B1/en active Active
- 2009-07-17 PT PT121815468T patent/PT2540350E/pt unknown
- 2009-07-17 EP EP12181533.6A patent/EP2540349B1/en active Active
- 2009-07-17 MX MX2011000826A patent/MX2011000826A/es active IP Right Grant
- 2009-07-17 SI SI200930956T patent/SI2540350T1/sl unknown
- 2009-07-17 KR KR1020117003982A patent/KR101313675B1/ko active Protection Beyond IP Right Term
- 2009-07-17 RS RS20140375A patent/RS53420B/en unknown
- 2009-07-17 RS RS20120463A patent/RS52534B/en unknown
- 2009-07-17 US US12/504,955 patent/US7973040B2/en active Active
- 2009-07-21 TW TW098124597A patent/TWI441638B/zh active
- 2009-07-21 AR ARP090102779A patent/AR072588A1/es active IP Right Grant
-
2011
- 2011-01-11 IL IL210580A patent/IL210580A/en active Protection Beyond IP Right Term
- 2011-01-13 TN TN2011000014A patent/TN2011000014A1/fr unknown
- 2011-01-19 CO CO11005448A patent/CO6351757A2/es active IP Right Grant
- 2011-01-19 NI NI201100023A patent/NI201100023A/es unknown
- 2011-01-20 DO DO2011000023A patent/DOP2011000023A/es unknown
- 2011-01-20 HN HN2011000209A patent/HN2011000209A/es unknown
- 2011-01-20 SV SV2011003813A patent/SV2011003813A/es unknown
- 2011-01-21 CL CL2011000145A patent/CL2011000145A1/es unknown
- 2011-01-21 EC EC2011010777A patent/ECSP11010777A/es unknown
- 2011-01-25 MA MA33556A patent/MA32502B1/fr unknown
- 2011-02-15 CR CR20110089A patent/CR20110089A/es unknown
- 2011-05-20 US US13/112,281 patent/US8080654B2/en active Active
-
2012
- 2012-10-26 HR HRP20120866AT patent/HRP20120866T1/hr unknown
- 2012-11-28 CY CY20121101150T patent/CY1113752T1/el unknown
-
2013
- 2013-01-15 HK HK13100580.1A patent/HK1173402A1/xx unknown
- 2013-01-15 HK HK13100581.0A patent/HK1173403A1/xx unknown
-
2014
- 2014-07-18 HR HRP20140693AT patent/HRP20140693T1/hr unknown
- 2014-08-01 CY CY20141100582T patent/CY1115503T1/el unknown
-
2016
- 2016-12-26 FR FR16C1027C patent/FR16C1027I2/fr active Active
- 2016-12-29 LT LTPA2016049C patent/LTC2310095I2/lt unknown
- 2016-12-30 NL NL300857C patent/NL300857I2/nl unknown
-
2017
- 2017-01-03 LU LU00002C patent/LUC00002I2/fr unknown
- 2017-01-10 HU HUS1700001C patent/HUS1700001I1/hu unknown
- 2017-01-20 NO NO2017004C patent/NO2017004I2/no unknown
- 2017-01-20 CY CY2017005C patent/CY2017005I1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528713A5 (ja) | ||
| JP2012513479A5 (ja) | ||
| HRP20120866T1 (hr) | Makrocikliäśni spojevi hinoksalina kao inhibitori hcv ns3 proteaze | |
| JP2013507439A5 (ja) | ||
| JP2009535352A5 (ja) | ||
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| JP2015512860A5 (ja) | ||
| JP2015024998A5 (ja) | ||
| RU2014122154A (ru) | Композиции, пригодные для лечения вирусных заболеваний | |
| HRP20151000T1 (hr) | Antivirusni spojevi | |
| IL207468A (en) | HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections | |
| JP2009511595A5 (ja) | ||
| JP2016508134A5 (ja) | ||
| JP2015517528A5 (ja) | ||
| EP2341065A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4a protease | |
| JP2012528161A5 (ja) | ||
| JP2014504643A5 (ja) | ||
| JP2008533007A5 (ja) | ||
| JP2013518107A5 (ja) | ||
| JP2013537905A5 (ja) | ||
| JP2013508279A5 (ja) | ||
| JP2012512169A5 (ja) | ||
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| RU2005126412A (ru) | Сор1 для лечения воспалительных заболеваний кишечника |